Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Tarveda Therapeutics, Inc

Tarveda Therapeutics, Inc. discovers and develops Pentarins®, a new class of potent and selective miniature drug conjugates with enhanced targeting capabilities for the treatment of a wide range of solid tumor cancers. Tarveda’s lead Pentarin drug candidate, PEN-221, is a miniature drug conjugate that targets the somatostatin receptor 2 (SSTR2) for treatment of patients with neuroendocrine, small cell lung, prostate, and other cancers that express SSTR2. PEN-221 comprises a highly selective peptide for SSTR2 conjugated to the potent cytotoxic payload, DM1, through a tuned cleavable linker. Tarveda is also advancing its Pentarin HSP90 drug conjugate platform with lead drug candidate PEN-866, which is a miniature drug conjugate that selectively binds to the intracellular target, Heat Shock Protein 90 (HSP90), and is linked to the payload SN-38, a potent topoisomerase I inhibitor.

  • Date:Monday, February 11
  • Time:2:15 PM - 2:30 PM
  • Room:Chelsea
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance:

    Click here.

  • Submission ID:22564
  • Company Presentation - Presentation Type:Privately Funded Company
  • Goal for Presentation:Private Corporate Update
  • Company Website:http://www.tarveda.com/
  • Company HQ City:Watertown
  • Company HQ State:Massachusetts
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:107,000,000
  • Previous and Current Investors:Flagship Pioneering, NanoDimension, New Enterprise Associates, Novo A/S, Versant Ventures
  • CEO/Top Company Official:Drew Fromkin, CEO
  • Year Founded:2012
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:PEN-221
  • Development Phase of Primary Product:Phase II
Speakers
Drew Fromkin
Tarveda Therapeutics
Back